Medipharm Labs Corp - Asset Resilience Ratio

Latest as of December 2025: 23.63%

Medipharm Labs Corp (LABS) has an Asset Resilience Ratio of 23.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medipharm Labs Corp working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CA$10.81 Million

≈ $7.82 Million USD Cash + Short-term Investments

Total Assets

CA$45.74 Million

≈ $33.09 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Medipharm Labs Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Medipharm Labs Corp assets under control.

Liquid Assets Composition Over Time

This chart breaks down Medipharm Labs Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore LABS long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$10.81 Million	23.63%
Short-term Investments	CA$0.00	0%
Total Liquid Assets	CA$10.81 Million	23.63%

Asset Resilience Insights

Good Liquidity Position: Medipharm Labs Corp maintains a healthy 23.63% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Medipharm Labs Corp Industry Peers by Asset Resilience Ratio

Compare Medipharm Labs Corp's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Medipharm Labs Corp (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Medipharm Labs Corp.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	23.63%	CA$10.81 Million ≈ $7.82 Million	CA$45.74 Million ≈ $33.09 Million	+1.87pp
2024-12-31	21.76%	CA$11.69 Million ≈ $8.46 Million	CA$53.73 Million ≈ $38.87 Million	-6.78pp
2023-12-31	28.54%	CA$18.25 Million ≈ $13.20 Million	CA$63.94 Million ≈ $46.25 Million	-9.48pp
2022-12-31	38.02%	CA$24.90 Million ≈ $18.01 Million	CA$65.50 Million ≈ $47.38 Million	-0.15pp
2021-12-31	38.17%	CA$35.25 Million ≈ $25.50 Million	CA$92.36 Million ≈ $66.81 Million	+19.59pp
2020-12-31	18.58%	CA$21.97 Million ≈ $15.89 Million	CA$118.23 Million ≈ $85.53 Million	-4.70pp
2019-12-31	23.28%	CA$39.31 Million ≈ $28.43 Million	CA$168.83 Million ≈ $122.13 Million	+4.44pp
2018-12-31	18.84%	CA$8.05 Million ≈ $5.82 Million	CA$42.73 Million ≈ $30.91 Million	--

pp = percentage points

About Medipharm Labs Corp

TO:LABS Canada Drug Manufacturers - Specialty & Generic

Market Cap

$21.51 Million

CA$29.74 Million CAD

Market Cap Rank

#24972 Global

#969 in Canada

Share Price

CA$0.07

Change (1 day)

+0.00%

52-Week Range

CA$0.06 - CA$0.09

All Time High

CA$7.17